CBI Scene Blog

Evanna Payen

Recent Posts

Current and Emerging Trends in Medical Publications

Posted by Evanna Payen on Sep 18, 2018 12:36:59 PM

The medical publications landscape is continually evolving, with various past challenges addressed by guidelines or standards, making them less of a concern in present-day practice. Still, new issues perpetually arise in this dynamic and ever-changing environment.

Read More

Topics: Publication Planning, Medical Affairs, Medical Publications

Direct-to-Patient, Remote Trials, Site-less Trials, and Digital Trials Different Ways of Saying 'Trial Success' and 'Positive Patient Experiences'

Posted by Evanna Payen on Jul 16, 2018 10:50:58 AM

CBI’s Direct-to-Patient Clinical Trials conference will address all these leading groundbreaking trials and help you keep pace with a rapidly changing frontier regardless of what terminology you utilize. For a quick look at how site-less, remote, digital, and direct-to-patient trials cover the same ground check out the trial definitions from industry leaders below.

Read More

Topics: Clinical

Q&A with Matthew Amsden, Founder and CEO of ProofPilot

Posted by Evanna Payen on Jun 25, 2018 1:03:06 PM

It's Gay Pride Month and events across the world celebrate wins and bring attention to issues that still need attention. The community still struggles with health disparities and the HIV epidemic. CBI Conference Producer, Trevor Sosvielle, sat down with Matthew Amsden, CEO of ProofPilot to chat about his early work in HIV prevention trials. He tells explains how these experiences helped shape ProofPilot and its patient-centric clinical trial approach.

Read More

Topics: Clinical

How to Align Management with Functional Areas of R&D

Posted by Evanna Payen on Apr 11, 2018 9:39:01 AM

While it's an issue that's not limited to the pharmaceutical industry, miscommunication between the "doers" - those actually performing clinical trials - and the "planners," who set and monitor the budget, is particularly prominent. While research and development in a non-pharmaceutical business can often be put on indefinite hold while funding is secured, clinical trials don't share that luxury. Variables such as timing, resources, and the ability to make adjustments if obstacles arise are freedoms all crucial to a given trial's success. This means, in turn, that "holding" isn't really a viable option. So how can the behind-the-scenes program teams work in tandem with those on the front lines?

Read More

Topics: Clinical, Finance, Compliance

GDPR's Impact on Consent Management and Data Privacy

Posted by Evanna Payen on Apr 2, 2018 10:13:30 AM

To say that global reporting requirements are constantly changing is something of an understatement, particularly as new markets around the world continue to emerge. As a result, many industry professionals are concerned about their own ability to keep up with and be aware of all new compliance requirements around the world - even if their businesses are based primarily within the United States.

Read More

Topics: Compliance

Importance of Listening to the "Voice of the Customer"

Posted by Evanna Payen on Jan 22, 2018 12:48:44 PM

When a consumer depends on something important - test results, medication, medical advice - they often feel vulnerable or anxious about the next step in the process. Suddenly, a routine customer service interaction, such as a question about shipments, becomes another potential point of anxiety. It's important that companies in the bio and pharma industries have the right individuals at that juncture, ready and willing to guide the apprehensive consumer to the solutions he or she needs to feel comfortable and respected.

Read More

Topics: Medical Affairs

Monitoring and Auditing with Limited Resources – How Often Should Comprehensive Risk Assessments Be Done?

Posted by Evanna Payen on Jan 16, 2018 2:43:54 PM

Comprehensive risk assessments always seem to make it onto a to-do list, but end up being considerably more difficult to take off of that same list. They take time, effort, and resources - the trinity of what runs competitive businesses in the pharmaceutical industry. It can be tempting to keep pushing them off, involving yourself in another one of the endless checkboxes to take care of - but that's a very bad idea. The very nature of risk assessments is to prevent that looming, nasty, "what if" that could derail your projects or dismantle your clinical trials. It's finding the leak before the pipe bursts, or detecting the first wisp of proverbial smoke before a fire can start in earnest. In other words, neglecting to iron out a regular schedule of risk assessment reports could have disastrous consequences.

Read More

Topics: Compliance

The Challenges of Scaling Up: Globalization of Call Centers

Posted by Evanna Payen on Jan 3, 2018 11:52:44 AM

If your business is approached the way that physical health would be, your call centers function as the nervous system, connecting all you do to the needs and feedback of your customer base. That's why globalization of your call centers should be approached carefully and with ample consideration. There are four key points you'll want to keep in mind throughout the planning and implementation stages of globalization efforts:

Read More

Topics: Medical Affairs

Moving from “Call Center” to Multi-Channel Center

Posted by Evanna Payen on Dec 4, 2017 10:34:26 AM

The concept of call centers is certainly nothing new in the Bio/Pharma sphere, but today's consumer is looking for more out of companies that help them handle their health. They don't simply want a contact point for immediate issues, they want guidance and support throughout their medical journey. This is an evolutionary challenge for traditional contact centers, a need that forces them to consider how they're currently interfacing with customers. This is the birth of the multi-channel movement, a philosophy that still provides the help and guidance of a phone-centric center with the flexibility modern patients expect.

Read More